FOSTER CITY, CA--(Marketwire - Dec 5, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 23^rd Annual Healthcare Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria Hotel in New York City.

To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ], under the Calendar of Events tab. A replay of the webcasts will be available one hour after the conclusion of the live events.

About SciClone

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN^® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit [ www.sciclone.com ].

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.

Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.